Featured Research

from universities, journals, and other organizations

No benefit of double dose antiviral drug for severe influenza, study suggests

Date:
May 30, 2013
Source:
BMJ-British Medical Journal
Summary:
There are no virological or clinical benefits of giving double doses of the antiviral drug oseltamivir (Tamiflu) to patients admitted to hospital with severe influenza, finds a large study from South East Asia.

This is the first study to examine the effectiveness of higher doses of oseltamivir in cases of hospitalized severe human influenza (seasonal, pandemic and bird flu strains). The authors say their findings have implications for global guidelines, clinical management and pandemic preparedness, including for the current H7N9 outbreak.

Human influenza is usually a self-limiting illness. Occasionally, however, it can lead to respiratory complications, admission to hospital, and death. Some studies suggest that, if given early, oseltamivir can help reduce mortality. This has led to suggestions to use double doses of the drug for severe influenza.

So researchers at the South East Asian Infectious Disease Clinical Research Network investigated whether double dose oseltamivir improves outcomes compared with the standard dose in patients admitted to hospital with severe influenza.

The study took place between April 2007 and February 2010 and involved 326 patients (mostly children aged under 15) with severe influenza at 13 hospitals in Indonesia, Singapore, Thailand and Vietnam.

Patients received either standard dose oseltamivir (75 mg twice a day or children's equivalent) or double dose (150 mg twice a day or children's equivalent) for five days. Nose and throat swabs were then taken to test for virus levels.

Other outcomes including death, admission to intensive care, and help with breathing (mechanical ventilation) were also assessed.

The researchers found no differences between the treatment groups in virus levels on day five. There were also no differences in deaths or rates of adverse events between the different doses.

The investigators say that the results "do not support routine use of double dose oseltamivir to treat severe influenza." And they conclude: "There are no virological or clinical advantages with double dose oseltamivir compared with standard dose in patients with severe influenza admitted to hospital."

In an accompanying editorial, Ian Barr and Aeron Hurt from the WHO Collaborating Centre for Reference and Research on Influenza say, despite some study limitations, what is clear is that double dose oseltamivir "is unlikely to significantly improve the clinical outcomes of severe cases of seasonal influenza."

These findings "could help to preserve oseltamivir stocks during a future pandemic … if clinicians were to prescribe only regular rather than double doses," they add. However, they stress that treatment options for patients with severe influenza "still need to be expanded" and that future studies "will hopefully lead to more effective treatments or better combinations of drugs."


Story Source:

The above story is based on materials provided by BMJ-British Medical Journal. Note: Materials may be edited for content and length.


Cite This Page:

BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. ScienceDaily, 30 May 2013. <www.sciencedaily.com/releases/2013/05/130530192427.htm>.
BMJ-British Medical Journal. (2013, May 30). No benefit of double dose antiviral drug for severe influenza, study suggests. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2013/05/130530192427.htm
BMJ-British Medical Journal. "No benefit of double dose antiviral drug for severe influenza, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/05/130530192427.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins